Derek Maetzold Sells 4,017 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 4,017 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the sale, the insider owned 87,715 shares in the company, valued at $3,509,477.15. This represents a 4.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Castle Biosciences Stock Up 0.2%

NASDAQ CSTL opened at $42.24 on Friday. The business has a fifty day moving average price of $39.20 and a two-hundred day moving average price of $28.27. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $43.01. The stock has a market capitalization of $1.23 billion, a PE ratio of -93.87 and a beta of 1.06.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%.The company had revenue of $80.55 million for the quarter, compared to analyst estimates of $71.06 million. Equities analysts expect that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. BTIG Research lifted their price target on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Robert W. Baird increased their price target on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. Zacks Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 2nd. Finally, Guggenheim upped their target price on Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.00.

Institutional Trading of Castle Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC raised its position in Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after purchasing an additional 1,391 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of Castle Biosciences during the third quarter worth about $35,000. CWM LLC lifted its stake in shares of Castle Biosciences by 80.6% in the third quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after acquiring an additional 853 shares during the period. Jones Financial Companies Lllp boosted its holdings in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Castle Biosciences by 63.7% in the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after acquiring an additional 976 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.